Overview

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
Phase:
Phase 3
Details
Lead Sponsor:
University of Cincinnati
Collaborators:
National Center for Advancing Translational Science (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
The LAM Foundation
Treatments:
Everolimus
Sirolimus